Comparison Overview

Hetero Drugs Ltd

VS

Cipla

Hetero Drugs Ltd

India Hyderabad, 500018, IN
Last Update: 2025-12-09
Between 750 and 799

Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,001
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Cipla

Lower Parel, Ganpatrao Kadam Marg,, Mumbai, Maharashtra, IN, 400013
Last Update: 2025-12-09
Between 750 and 799

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 49,702
Subsidiaries: 7
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/hetero-drugs-ltd.jpeg
Hetero Drugs Ltd
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/cipla.jpeg
Cipla
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Hetero Drugs Ltd
100%
Compliance Rate
0/4 Standards Verified
Cipla
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Hetero Drugs Ltd in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Cipla in 2025.

Incident History — Hetero Drugs Ltd (X = Date, Y = Severity)

Hetero Drugs Ltd cyber incidents detection timeline including parent company and subsidiaries

Incident History — Cipla (X = Date, Y = Severity)

Cipla cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/hetero-drugs-ltd.jpeg
Hetero Drugs Ltd
Incidents

No Incident

https://images.rankiteo.com/companyimages/cipla.jpeg
Cipla
Incidents

No Incident

FAQ

Cipla company demonstrates a stronger AI Cybersecurity Score compared to Hetero Drugs Ltd company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Cipla company has disclosed a higher number of cyber incidents compared to Hetero Drugs Ltd company.

In the current year, Cipla company and Hetero Drugs Ltd company have not reported any cyber incidents.

Neither Cipla company nor Hetero Drugs Ltd company has reported experiencing a ransomware attack publicly.

Neither Cipla company nor Hetero Drugs Ltd company has reported experiencing a data breach publicly.

Neither Cipla company nor Hetero Drugs Ltd company has reported experiencing targeted cyberattacks publicly.

Neither Hetero Drugs Ltd company nor Cipla company has reported experiencing or disclosing vulnerabilities publicly.

Neither Hetero Drugs Ltd nor Cipla holds any compliance certifications.

Neither company holds any compliance certifications.

Cipla company has more subsidiaries worldwide compared to Hetero Drugs Ltd company.

Cipla company employs more people globally than Hetero Drugs Ltd company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Hetero Drugs Ltd nor Cipla holds SOC 2 Type 1 certification.

Neither Hetero Drugs Ltd nor Cipla holds SOC 2 Type 2 certification.

Neither Hetero Drugs Ltd nor Cipla holds ISO 27001 certification.

Neither Hetero Drugs Ltd nor Cipla holds PCI DSS certification.

Neither Hetero Drugs Ltd nor Cipla holds HIPAA certification.

Neither Hetero Drugs Ltd nor Cipla holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

PCSX2 is a free and open-source PlayStation 2 (PS2) emulator. In versions 2.5.377 and below, an unchecked offset and size used in a memcpy operation inside PCSX2's CDVD SCMD 0x91 and SCMD 0x8F handlers allow a specially crafted disc image or ELF to cause an out-of-bounds read from emulator memory. Because the offset and size is controlled through MG header fields, a specially crafted ELF can read data beyond the bounds of mg_buffer and have it reflected back into emulated memory. This issue is fixed in version 2.5.378.

Risk Information
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:L/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Aircompressor is a library with ports of the Snappy, LZO, LZ4, and Zstandard compression algorithms to Java. In versions 3.3 and below, incorrect handling of malformed data in Java-based decompressor implementations for Snappy and LZ4 allow remote attackers to read previous buffer contents via crafted compressed input. With certain crafted compressed inputs, elements from the output buffer can end up in the uncompressed output, potentially leaking sensitive data. This is relevant for applications that reuse the same output buffer to uncompress multiple inputs. This can be the case of a web server that allocates a fix-sized buffer for performance purposes. There is similar vulnerability in GHSA-cmp6-m4wj-q63q. This issue is fixed in version 3.4.

Risk Information
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A vulnerability was found in itsourcecode COVID Tracking System 1.0. Affected by this vulnerability is an unknown functionality of the file /admin/?page=zone. The manipulation of the argument ID results in sql injection. The attack may be launched remotely. The exploit has been made public and could be used.

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A vulnerability has been found in itsourcecode COVID Tracking System 1.0. Affected is an unknown function of the file /admin/login.php of the component Admin Login. The manipulation of the argument Username leads to sql injection. The attack may be initiated remotely. The exploit has been disclosed to the public and may be used.

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A flaw has been found in campcodes Online Student Enrollment System 1.0. This impacts an unknown function of the file /admin/register.php. Executing manipulation of the argument photo can lead to unrestricted upload. The attack can be launched remotely. The exploit has been published and may be used.

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X